GlassScriptPhysician profile
Robert Christopher Spears
NPI 1174985592
$3,068.48
in general payments reported to CMS, 2019-2025
13 companies · $844 in 2025
The $844 reported for 2025 was more than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.56 · 2023: $1,804 · 2024: $405 · 2025: $844.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,015 · Food and Beverage: $1,037.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,015.45 |
| Food and Beverage | $1,037.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $1,431.75 | 2023 | Viper |
| Depuy Synthes Sales INC. | $411.65 | 2023-2025 | Teligen, Fibergraft Aeridyan Matrix, Expedium Verse |
| Blue Surgical LLC | $408.96 | 2025 | |
| Arthrex, INC. | $288.20 | 2025 | |
| Boston Scientific Corporation | $139.16 | 2024 | |
| Stryker Corporation | $107.25 | 2024-2025 | Core |
| Nevro Corp. | $90.29 | 2023 | Senza |
| Medtronic, INC. | $54.25 | 2024 | Midas Rex, Navlock |
| Centinel Spine, LLC | $50.37 | 2024 | Prodisc C Vivo |
| Depuy Synthes Products, INC. | $37.17 | 2024 | Velys |
| Abbott Laboratories | $18.66 | 2023 | Eterna |
| Abbvie INC. | $15.56 | 2021 | |
| Jazz Pharmaceuticals INC. | $15.21 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Spears listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.